In vitro activity of S-(3,4-dichlorobenzyl)isothiourea hydrochloride and novel structurally related compounds against multidrug-resistant bacteria, including Pseudomonas aeruginosa and Burkholderia cepacia complex

International Journal of Antimicrobial Agents

Volumn 39, Issue 1, 2012, Pages 27-32

  Nicholson, Audrey ^a   Perry, John D ^a,b   James, Arthur L ^b   Stanforth, Stephen P ^b   Carnell, Sonya ^c   Wilkinson, Kathryn ^a   Anjam Khan, C M ^c   De Soyza, Anthony ^a,d   Gould, F Kate ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

^b NORTHUMBRIA UNIVERSITY   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Antimicrobial resistance; Minimum inhibitory concentration; Pseudomonas aeruginosa; Susceptibility testing

Indexed keywords

(2,3,4,5,6 PENTAFLUOROBENZYL)ISOTHIOUREA HYDROBROMIDE; (2,4 DICHLOROBENZYL)ISOTHIOUREA; (3,4 DICHLOROBENZYL)ISOTHIOSEMICARBAZIDE; (3,4 DICHLOROBENZYL)ISOTHIOUREA; (3,4 DIFLUOROBENZYL)ISOTHIOUREA HYDROBROMIDE; (4 BROMOBENZYL)ISOTHIOUREA HYDROBROMIDE; (4 CHLOROBENZYL) N (2,4 DICHLOROPHENYL)ISOTHIOUREA; (4 CHLOROBENZYL) N (4 CHLOROPHENYL)ISOTHIOUREA; (4 CHLOROBENZYL) N ETHYLISOTHIOUREA; (4 CHLOROBENZYL)ISOTHIOUREA; (4 CHLOROPHENYL)THIOUREA; (4 CYANOBENZYL)ISOTHIOUREA HYDROBROMIDE; (4 FLUOROBENZYL)ISOTHIOUREA HYDROBROMIDE; (4 METHOXYBENZYL)ISOTHIOUREA; [(7 METHOXYCOUMARIN 4 YL)METHYL]ISOTHIOUREA HYDROBROMIDE; [(COUMARIN 7 YL)METHYL]ISOTHIOUREA HYDROBROMIDE; AMIKACIN; AZTREONAM; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; MEROPENEM; MINOCYCLINE; PIPERACILLIN PLUS TAZOBACTAM; THIOUREA DERIVATIVE; TIMENTIN; TOBRAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACINETOBACTER BAUMANNII; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; BURKHOLDERIA CEPACIA; CONTROLLED STUDY; CORYNEBACTERIUM DIPHTHERIAE; CYSTIC FIBROSIS; DRUG STRUCTURE; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; GENETIC ANALYSIS; GRAM NEGATIVE BACTERIUM; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; LISTERIA MONOCYTOGENES; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROVIDENCIA RETTGERI; PSEUDOMONAS AERUGINOSA; SALMONELLA TYPHIMURIUM; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PYOGENES; YERSINIA ENTEROCOLITICA;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BURKHOLDERIA CEPACIA COMPLEX; CYSTIC FIBROSIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; THIOUREA;

EID: 82955203738     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2011.08.015     Document Type: Article

References (21)

1. D.M. Livermore Has the era of untreatable infections arrived? J Antimicrob Chemother 64 Suppl. 1 2009 i29 i36
2. H.W. Boucher, G.H. Talbot, J.S. Bradley, J.E. Edwards, D. Gilbert, and L.B. Rice Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America Clin Infect Dis 48 2009 1 12
3. T.R. Walsh Emerging carbapenemases: a global perspective Int J Antimicrob Agents 36 Suppl. 3 2010 S8 S14
4. J.E. McGowan Resistance in non-fermenting Gram-negative bacteria: multidrug resistance to the maximum Am J Med 119 Suppl. 1 2006 S29 S36
5. J.R.W. Govan, A.R. Brown, and A.M. Jones Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection Future Microbiol 2 2007 153 164 (Pubitemid 46766989)
6. M.E. Falagas, and I.A. Bliziotis Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? Int J Antimicrob Agents 29 2007 630 636 (Pubitemid 46710354)
7. N. Iwai, K. Nagai, and M. Wachi Novel S-benzylisothiourea compound that induces spherical cells in Escherichia coli probably by acting on a rod-shape-determining protein(s) other than penicillin-binding protein 2 Biosci Biotechnol Biochem 66 2002 2658 2662 (Pubitemid 39251140)
8. A. De Soyza, A. McDowell, L. Archer, J.H. Dark, S.J. Elborn, and E. Mahenthiralingam Burkholderia cepacia complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis Lancet 24 2001 1780 1781 (Pubitemid 33153006)
9. A. De Soyza, K. Morris, A. McDowell, C. Doherty, L. Archer, and J. Perry Prevalence and clonality of Burkholderia cepacia complex genomovars in UK patients with cystic fibrosis referred for lung transplantation Thorax 59 2004 526 528 (Pubitemid 38797528)
10. A. De Soyza, G. Meachery, K.L. Hester, A. Nicholson, G. Parry, and K. Tocewicz Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: a single-center experience J Heart Lung Transplant 29 2010 1395 1404
11. J.M. Andrews Determination of minimum inhibitory concentrations J Antimicrob Chemother 48 Suppl. 1 2001 5 16 Erratum in: J Antimicrob Chemother 2002;49:1049
12. J.M. Andrews BSAC Working Party on Susceptibility Testing BSAC standardized disc susceptibility testing method (version 7) J Antimicrob Chemother 62 2008 256 278 (Pubitemid 351984768)
13. S.D. Aaron, W. Ferris, D.A. Henry, D. Speert, and N.E. MacDonald Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia Am J Respir Crit Care Med 161 2000 1206 1212 (Pubitemid 30243831)
14. N. Iwai, T. Ebata, H. Nagura, T. Kitazumi, K. Nagai, and M. Wachi Structure-activity relationship of S-benzylisothiourea derivatives to induce spherical cells in Escherichia coli Biosci Biotechnol Biochem 68 2004 2265 2269 (Pubitemid 40033499)
15. Z. Kazimierczuk, M. Chalimoniuk, A.E. Laudy, R. Moo-Puc, R. Cedillo-Rivera, and B.J. Starosciak Synthesis and antimicrobial and nitric oxide synthase inhibitory activities of novel isothiourea derivatives Arch Pharm Res 33 2010 821 830
16. W.E. Regelmann, G.R. Elliott, W.J. Warwick, and C.C. Clawson Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone Am Rev Respir Dis 141 1990 914 921 (Pubitemid 20157719)
17. A. Oliver, B.R. Levin, C. Juan, F. Baquero, and J. Blázquez Hypermutation and the preexistence of antibiotic-resistant Pseudomonas aeruginosa mutants: implications for susceptibility testing and treatment of chronic infections Antimicrob Agents Chemother 48 2004 4226 4233 (Pubitemid 39434879)
18. V. Boussaud, R. Guillemain, D. Grenet, N. Coley, R. Souilamas, and P. Bonnette Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres Thorax 63 2008 732 737
19. B.D. Alexander, E.W. Petzold, L.B. Reller, S.M. Palmer, R.D. Davis, and C.W. Woods Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex Am J Transplant 8 2008 1025 1030 (Pubitemid 351537763)
20. J.B. Orens, M. Estenne, S. Arcasoy, J.V. Conte, P. Corris, and J.J. Egan International guidelines for the selection of lung transplant candidates: 2006 update - a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation J Heart Lung Transplant 25 2006 745 755 (Pubitemid 43963375)
21. M.J. Hall, R.F. Middleton, and D. Westmacott The fractional inhibitory concentration (FIC) index as a measure of synergy J Antimicrob Chemother 11 1983 427 433 (Pubitemid 13094077)